Vuong Trieu Purchases Shares of Oncotelic Therapeutics
CEO Vuong Trieu bought 75,000 shares of Oncotelic Therapeutics at $0.05 each.
Key Points
- Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, purchased 75,000 shares at $0.05 each on June 23, 2026.
- Shares of OTCQB:OTLC traded near $0.05 on Thursday, with a market cap of approximately $22.2 million.
- No new analyst ratings were reported, and Oncotelic does not currently pay a dividend.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, Vuong Trieu, the Chairman and CEO of Oncotelic Therapeutics, Inc. (OTC Markets OTCQB: OTLC), purchased 75,000 shares of the company at $0.05 each. This transaction was valued at $3,750 and was not part of a pre-planned trading program.
Insider Buying and Selling at Oncotelic Therapeutics, Inc.
In addition to the purchase on June 23, Vuong Trieu made several other transactions recently. On June 24, he bought 115,000 shares at the same price, and on June 22, he acquired 65,000 shares. Earlier, on June 17, he purchased 239,759 shares at $0.04 each. Amit Shah, the CFO, also bought 20,000 shares at $0.05 on June 22.
Oncotelic Therapeutics, Inc. Stock Up 33.3%
Shares of OTCQB:OTLC traded near $0.05 on Thursday. Oncotelic Therapeutics has a market cap of approximately $22.2 million and a P/E ratio of 0.08. The stock's 52-week range is between $0.02 and $0.11, with a 50-day moving average of $0.05 and a 200-day moving average of $0.07. The company has a beta of -0.317, indicating lower volatility compared to the market.
$OTLC stock price
Daily closing prices, year to date. Not investment advice.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Agoura Hills, California. It focuses on developing drugs for orphan oncology indications. The company is working on several drug candidates, including OT-101 for certain cancers and OXi4503 for acute myeloid leukemia. Led by CEO Dr. Vuong Trieu, the company employs 38 people and aims to target both cancer and viral diseases with its innovative therapies.
Bottom Line
Vuong Trieu's recent share purchases reflect his ongoing support and confidence in Oncotelic Therapeutics. Investors keep a close eye on insider transactions like these for insights into how company leaders view the future. While the stock trades at a low price, its market cap and P/E ratio offer a glimpse into its current valuation. As always, insider buying doesn't necessarily indicate future performance, but it is a data point that many investors find useful.
Get Oncotelic Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OTLC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.